Tengion, a clinical-stage biotechnology company, is a leader in developing neo-organs and neo-tissues, currently derived from a patient's own (autologous) cells. The Company has initiated a Phase 1 clinical trial for the Tengion Neo-Urinary Conduit™ in bladder cancer patients requiring bladder removal. The Company has completed two Phase 2 human clinical trials in the United States with its Tengion Neo-Bladder Augment™ for children with neurogenic bladder due to spina bifida and in adults with neurogenic ...

Contact Information

2900 Potshop Lane
Suite 100
East Norriton, PA 19403

tel: 610-292-8364


Investor Relations

Tengion, Inc.
Linda B. Hearne, Vice President - Finance
e-mail: ir@tengion.com


Exchange: NASDAQ
Industry: Medical Laboratories & Research
Market Cap: $44.5M

The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.